On August 30, the U.S. Food and Drug Administration approved tisagenlecleucel for pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL). That approval came after positive clinical trial results with chimeric antigen receptor (CAR) T-cell therapies last spring and summer increased dramatically.

中文翻译：

---

首个嵌合抗原受体T细胞疗法获得批准

8月30日，美国食品药品监督管理局批准了替萨根微核素用于复发或难治性急性淋巴细胞白血病（ALL）的小儿患者。去年春天和夏天，嵌合抗原受体（CAR）T细胞疗法取得了积极的临床试验结果之后，这项批准才获得批准。